WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on February 26, 2021 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 24, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End Full Approval Pathway for IMGN632 in BPDCN Aligned with FDA; Updated Phase 1/2 Data in BPDCN Presented at ASH Balance Sheet Funds Operations into the Second
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 11, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 29, 2021 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 29, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 30, 2020-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 39 th Annual J.P.
Updated Data Demonstrating Favorable Safety Profile and Encouraging Monotherapy Activity in BPDCN Presented During Oral Session Preclinical Combination Data in Relapsed/Refractory AML Support Further Evaluation of Triplet; Trial in Progress Poster for Phase 1b/2 Study Presented Conference Call to
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 1, 2020-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 30, 2020 the compensation committee of the Company’s Board of Directors granted